User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

10531

Interactions with Platform & by Email *

INTERACTIONS

1264

Unique # Participated *

PARTICIPANTS

316

Responses Validated *

VALIDATIONS

34

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
HIV Antivirals.....I-3
  
   NRTIs.....I-4
NNRTIs.....I-4
Protease Inhibitor (PI).....I-4
Other HIV Antivirals.....I-4
Hepatitis B & C Antivirals.....I-4
  
   Hepatitis B Antivirals.....I-5
Hepatitis C Antivirals.....I-5
Herpes Simplex Virus (HSV) Antivirals.....I-5
Influenza Antivirals.....I-5
  
   Respiratory Syncytial Virus (RSV) Antivirals.....I-6
Human Papilloma Virus (HPV) Antivirals.....I-6
Other Antivirals.....I-6
  
   Viruses, a Difficult – to – Treat Class of Parasites.....II-1
United States - The Largest Market for Antivirals Globally.....II-1
1$100
   Five Major Antivirals Dominate the Overall Antivirals Arena.....II-2
Table 1: Worldwide Infectious Disease Drugs Market by Class: 2005 Percentage Share Breakdown by Type for Antivirals, Quinolones, Macrolides, Penicillins, Cephalosporins, Antifungals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart).....II-2
Anti-HIV Drugs – The Largest Antivirals Category Worldwide.....II-2
1$350
   US - Largest Region, and Japan - Fastest Growing Region for HIV Antivirals.....II-3
Table 2: World HIV Antivirals Market by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart).....II-3

Table 3: World HIV Antivirals Market by Geographic Region – Percentage Share Breakdown for US, Japan, Europe, and Rest of World (excluding Japan) for the Year 2006 (includes corresponding Graph/Chart).....II-3
1$350
   Leading Players and Drugs.....II-4
Top 10 HIV Antiviral Drug Candidates by Global Sales.....II-4
New Drugs in Pipeline to Boost up the HIV Antivirals Sales.....II-4
Hepatitis Antivirals – A Significant Market.....II-4
1$100
   US Dominates the Hepatitis B & C Antivirals Market.....II-5
Table 4: World Hepatitis B & C Antivirals Market by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart).....II-5
Hepatitis C Antivirals - The Fastest Growing Antivirals Segment.....II-5
1$350
   U S Dominates the Hepatitis C Antivirals Market.....II-6
Table 5: World Hepatitis C Antivirals Market by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart).....II-6
The US Dominates the Hepatitis B Antivirals Market.....II-6
1$350
   Table 6: World Hepatitis B Antivirals Market by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart).....II-7
Growing Patient Population to Drive up Hepatitis B Drugs Market.....II-7
Influenza Anti-Virals.....II-7
Rising Threat of Avian Flu to Drive up the Market for Antivirals.....II-7
1$350
   Herpes and Respiratory Antivirals.....II-8
HSV/VZV Drugs Dominate the Herpes and Respiratory Antivirals Market.....II-8
Launch of New Drugs to Drive up the Market for Respiratory Antivirals.....II-8
1$100
   Competitive Landscape.....II-91$100
   Players Active in the HIV Antivirals Market.....II-10
Table 7: Leading Drug Brands for HIV Infection in the World: 2005 Sales (in $ million) for Combivir, Kaletra, Viread, Reyataz, Sustiva, Trizivir, Epivir, and Epzicom/ Kivexa (includes corresponding Graph/Chart).....II-10
Major HIV Antivirals Brands Available in the Market.....II-10
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Brands –.....II-10
Epivir (Lamivudine).....II-10
Retrovir (Zidovudine).....II-10
1$350
   Combivir (Epivir+Retrovir).....II-11
Videx (Didanosine).....II-11
Zerit (Stavudine).....II-11
Hivid (Zalcitabine).....II-11
Protease Inhibitors (PIs) -.....II-11
Norvir (Ritonavir).....II-11
Kaletra (Lopinavir+Ritonavir).....II-11
Agenerase (Amprenavir).....II-11
1$100
   (VX-175) Fosamprenavir.....II-12
VX-385.....II-12
Fusion Inhibitors -.....II-12
Fuzeon (Enfuvirtide).....II-12
Players Active in the Hepatitis B Virus (HBV) Drugs Market..II-12
Hepsera Leads the Oral Hepatitis B Antivirals Market...II-12
Table 8: Leading Drug Brands for Oral Hepatitis B Antivirals: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart).....II-12
1$350
   Table 9: Leading Antivirals Brands for Hepatitis B Infection in the World: 2005 Sales (in $million) for *Engerix-B, Havrix, and Twinrix; **Infanrix and Pediarix, and Epivir (includes corresponding Graph/Chart).....II-13
Players in the Hepatitis C Virus (HCV) Drugs Market.....II-13
Table 10: Leading Drug Brands for Oral Hepatitis B Antivirals in the World: 2005 Sales (in $million) for Pegasys and PEG-Intron.....II-13
1$350
   Table 11: Leading Players in the Pegylated Interferons Market in the World: 2006 Percentage Share Breakdown by Player for Hoffmann-La Roche, Schering-Plough and Others (includes corresponding Graph/Chart).....II-14

Table 12: Leading Therapies for Hepatitis C Infection in the World: 2006, 2010E and 2015E Percentage Share Breakdown for Ribavirin, Interferons, Protease Inhibitors, and Nucleoside Analogs (includes corresponding Graph/Chart).....II-14
1$350
   Players in the Herpes and Respiratory Antiviral Market.....II-15
Table 13: Leading Brands of the Respiratory Antivirals Market in the World: 2005 Sales (in $million) for Tamiflu; Synagis; Infanrix and Pediarix (includes corresponding Graph/Chart).....II-15
Players in the Herpes Simplex Virus (HSV) Therapies Market.....II-15
1$350
   Table 14: Leading Drug Brands for Oral Herpes Antivirals in the World: 2004 Sales (in $million) for Valtrex and Zovirax.....II-16
Major HSV Infection Drugs Available.....II-16
Zovirax (Aciclovir).....II-16
Famvir (Famciclovir).....II-16
Foscavir (Foscarnet).....II-16
Valtrex (Valaciclovir).....II-16
1$350
   Vectavir/Denavir (Penciclovir).....II-17
Abreva (Docosanol).....II-17
Players in the Influenza Market.....II-17
Major Influenza Drugs Available.....II-17
Symmetrel® (Amantadine).....II-17
Flumadine (Rimantadine).....II-17
Tamiflu (Oseltamivir).....II-17
1$100
   Relenza (Zanamivir).....II-18
Players in the Antivirals (Non-HIV) Market.....II-18
Table 15: Global Leading Players in the Antivirals (Non-HIV) Market: 2005 Percentage Share Breakdown for GlaxoSmithKline (GSK), Novartis, Roche, Schering-Plough and Others (includes corresponding Graph/Chart).....II-18
Players Active in the Antiviral Vaccines Market.....II-18
1$350
   Table 16: Leading Antiviral Vaccines Sales (in US$ million) in US/Europe in 2003 (includes corresponding Graph/Chart).....II-19

Table 17: Leading Players in the US & **5EU Vaccines Markets: 2005 Percentage Share Breakdown by Player for GlaxoSmithKline (GSK), Sanofi-Aventis, Merck, *Novartis (Chiron) and Others (includes corresponding Graph/Chart).....II-19
1$350
   Product Pipeline Development of Hepatitis C Drugs as of 2006.....II-20
1$100
   Increased Investment in R&D to Fuel Growth.....II-21
Preventative Antivirals Gains Significance.....II-21
New Drug Types Fuels Up the HIV Drugs Sector.....II-21
1$100
   Development of Direct Targeted Antiviral Therapies.....II-22
Advent of Novel Anti-Viral Peptides.....II-22
1$100
   siRNA Shows Potential to Function as Antiviral Agent.....II-23
Reduction of HIV/AIDS Therapy Costs Boost Market Growth.....II-23
Combination Drug Therapy Gains Popularity in the Anti-HIV Drugs Market.....II-23
Empowering Women to Fight Against Spread of HIV Infection.....II-23
1$100
   Prices to Go Up for Novel Antivirals.....II-24
Competition Scales up for Nucleoside/Nucleotide Analogs Class of Hepatitis Antivirals.....II-24
Emergence of Oligonucleotide (ODN) Agents in HIV Drugs Market.....II-24
PMBs to Invade the Antivirals Market.....II-24
Acute Shortage Witnessed for the Influenza Vaccine for the 2004-05 Season.....II-24
1$100
   New Therapies for Treatment Naïve Hepatitis Patients.....II-25
Adult and Travel Vaccines to Drive Up the Market for Antiviral Vaccines.....II-25
Researches to Develop Antivirals for Other Miscellaneous Viral Diseases on Full Swing.....II-25
Growth to Slow Down Considerably for Herpes Antiviral Market.....II-25
STDs, a Major Concern the World Over.....II-25
1$100
   Microbiocides, a New Way to Fight STD and HIV Infections.....II-26
Spread of HIV Infection Poses a Global Health Risk.....II-26
2$200
   HIV/AIDS Pandemics.....II-28
HIV/AIDS Cases for 2005 in the World.....II-28
Highlights of AIDS Epidemic.....II-28
1$100
   Table 18: Global HIV/AIDS Statistics in 2005 (in Million) (includes corresponding Graph/Chart).....II-291$350
   Table 19: Regional Statistics for HIV/AIDS Cases in 2005 (in Million) (includes corresponding Graph/Chart).....II-30

Table 20: Deaths Due to AIDS Worldwide: Breakdown by Region– 2004 (in Million) (includes corresponding Graph/Chart).....II-30
1$350
   Table 21: HIV/AIDS Cases in Adults and Children Worldwide: Breakdown by Region-End 2004.....II-31

Table 22: Countries With the Highest Number of People Living with HIV: 2003 (includes corresponding Graph/Chart).....II-31
1$350
   Various Organizations Actively Supports HIV/AIDS Awareness and Preventive Measures Programs.....II-32
Table 23: Regional Distribution of Requirement of Funding for Prevention of AIDS: Percentage Share Breakdown for Africa, East Asia-Pacific, South & South East Asia, Eastern Europe, Latin America & Caribbean Region, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart).....II-32

Table 24: Regional Distribution of Requirement of Funding for Treatment and Care of AIDS: Percentage Share Breakdown for Africa, Latin America & Caribbean Region, East Asia-Pacific, Eastern Europe, South & South East Asia, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart).....II-32
Hepatitis B Virus (HBV) Infection Epidemic.....II-32
1$350
   Hepatitis C Virus (HCV) Infection Epidemic.....II-33
Table 25: Diagnosis of Hepatitis C Infection in the World: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Sexual Contact, Contaminated Blood Transfusion and Others (includes corresponding Graph/Chart).....II-33
1$350
   Influenza – Major Outbreaks.....II-34
1$100
   What are Viruses?.....II-35
RNA & DNA Viruses.....II-35
Emergence of Antivirals.....II-35
1$100
   Functions of Antivirals.....II-36
Design Strategies for Antivirals Drugs.....II-36
Vaccines, the Antivirals for Initial Stage of Viral Infection.....II-36
Antivirals for Other Stages of Viral Life Cycle.....II-36
Entry Blockers.....II-36
1$100
   Viral Component Replication Blockers.....II-37
Viral Component Assimilation Blockers.....II-37
Antisense Molecules.....II-37
Synthetic Ribozymes.....II-37
1$100
   Protease Inhibitors.....II-38
Blockers for Release of Completed Viruses from the Host Cell.....II-38
Other Types of Antivirals.....II-38
Interferons.....II-38
Synthetic Monoclonal Antibodies.....II-38
Factors Governing Developments in Antiviral Technology.....II-38
1$100
   Human Immunodeficiency Virus (HIV).....II-39
Transmission of HIV Infection.....II-39
1$100
   Infection Process - Targets for HIV Therapy.....II-40
Symptoms of the Infection.....II-40
1$100
   Most Vulnerable Demographics for HIV Infection.....II-411$100
   Preventive Methods for Controlling HIV Infection.....II-42
Methods for the Measurement of Viral Load in Patients.....II-42
Methods for Determining Drug Resistance in HIV Positive Patients.....II-42
1$100
   Major HIV/AIDS Testing Methods Available.....II-43
Diagnostic Tests.....II-43
I. Antibody Tests.....II-43
A. HIV-1 Screening Tests.....II-43
a. Enzyme-linked Immunosorbent Assays/ Enzyme Immunoassays (ELISA/EIA).....II-43
1$100
   b. Home AccessHIV-1 test system/Dried Blood Spot.....II-44
c. Rapid Tests........II-44
B. HIV-1 Antibody Confirmatory Tests.....II-44
a. The Western Blot Test.....II-44
b. Indirect Immunofluorescent Antibody Assay (IFA).....II-44
1$100
   c. Line Immunoassay.....II-45
d. Radioimmunoprecipitation Assay (RIPA).....II-45
C. HIV-2 Diagnostic Tests and HIV Group “O.....II-45
Major Trends in the HIV/AIDS Testing Market.....II-45
Rapid Testing- Displays High Potential.....II-45
1$100
   FDA Approved Rapid HIV Tests in US.....II-46
Molecular Diagnostics Register Strong Growth in Blood Screening Markets.....II-46
Ultra-Rapid HIV-screening tests- A Strong Fight against HIV-Epidemic.....II-46
Emergency Room Testing to Help HIV Diagnosis.....II-46
Treatments Available for HIV/AIDS Infections.....II-46
1$100
   Major HIV/AIDS Drug Categories Available.....II-47
NRTIs.....II-47
NNRTIs.....II-47
GW695634.....II-47
1$100
   Protease Inhibitor (PI).....II-48
(VX-175) Fosamprenavir.....II-48
VX-385.....II-48
Integrase Inhibitors (IIs).....II-48
S-1360.....II-48
Entry Blockers.....II-48
1$100
   Fusion Inhibitors.....II-49
Fuzeon (Enfuvirtide).....II-49
Antiviral siRNAs.....II-49
New Products in Pipeline.....II-49
HIV Vaccines.....II-49
1$100
   Hepatitis Infection.....II-50
Acute Hepatitis Infection.....II-50
Chronic Hepatitis Infection.....II-50
Treatment Regimens for Hepatitis Infection.....II-50
Interferons.....II-50
1$100
   Standard Interferons.....II-51
Pegylated Interferons.....II-51
Pegasys.....II-51
N & PEG-Intron Redipen.....II-51
Pegasys Pack.....II-51
N & Pegatron.....II-51
Ribavirin.....II-51
1$100
   Types of Hepatitis Infection based on Strains.....II-52
Hepatitis A Virus (HAV) Infection.....II-52
Hipatitis B Virus.....II-52
Hepatitis B Virus (HBV) Infection.....II-52
Treatments Available for Chronic HBV Infection.....II-52
Vaccines Dominates the Category.....II-52
1$100
   Antiviral Drugs Available.....II-53
Hepatitis C Virus (HCV) Infection.....II-53
Treatments Available for Chronic Hepatitis C Infection.....II-53
1$100
   Products in Pipeline.....II-54
Some Alternative Treatments.....II-54
Hepatitis D Virus (HDV) Infection.....II-54
1$100
   Hepatitis E Virus (HEV) Infection.....II-55
Herpes Simplex Virus (HSV) Infection.....II-55
HSV-1 Infection.....II-55
1$100
   HSV-2 Infection.....II-56
Neonatal Herpes Simplex Infection.....II-56
Treatments Available for HSV Infection.....II-56
Table Containing Major HSV Drugs along with their Patent Expiry Dates.....II-56
1$100
   HSV Antivirals Available in the Market.....II-57
Treatments for Opthalmic Viral Infections.....II-57
Cytovene (Ganciclovir).....II-57
Vistide (Cidofovir).....II-57
Foscavir (Foscarnet).....II-57
1$100
   Vaccines Against HSV Infection.....II-58
Respiratory Viruses Infections.....II-58
Influenza Virus.....II-58
1$100
   Influenza A Virus.....II-59
Avian Flu.....II-59
Influenza – Brief History.....II-59
Transmission of Influenza Infection.....II-59
Treatments for Respiratory Viruses.....II-59
1$100
   Influenza Vaccines.....II-60
Respiratory Syncytial Virus (RSV) Infection.....II-60
1$100
   Other Respiratory Viruses.....II-61
Treatments for RSV and other Respiratory Viral Infections.....II-61
Human Papilloma Virus (HPV).....II-61
Treatments Available for HPV Infection.....II-61
1$100
   Other Types of Viral Diseases.....II-62
Treatment Options Available for Other Types of Viral Diseases.....II-62
Overview of Antiviral Vaccines.....II-62
2$200
   UNHCR .....II-64
UNICEF.....II-64
WFP.....II-64
UNDP.....II-64
1$100
   UNPF.....II-65
UNODC.....II-65
ILO .....II-65
UNESCO.....II-65
WHO.....II-65
1$100
   World Bank.....II-66
National AIDS Trust.....II-66
1$100
   Bristol-Myers Unveils Baraclude in India.....II-67
Chinese and US Researchers Together Develop Purified Antiviral Compounds.....II-67
Celldex to Develop a Fusion Protein CDX 2401.....II-67
PDSC Launches a Germicidal Disinfectant, Medic Kleen.....II-67
REPLICor to Develop Antiviral Drugs.....II-67
1$100
   Valeant Pharmaceuticals to Develop Viramidine(R).....II-68
Biota Discovers a New Group of Antiviral Drugs against RSV.....II-68
Serum Launches Q-Vac, a Combination Vaccine.....II-68
Chongqing Jiachen to Produce Hepatitis B Vaccine.....II-68
IIL Decides to Roll Out Five Vaccines in Indian Market.....II-68
1$100
   Shanta Biotechnics to Foray into US Markets with AlphaFeto and Shanvac B.....II-69
GSK Launches Hepsera for Chronic Hepatitis B.....II-69
Viral Therapeutics Takes Over Development Rights to Recombinant Human Protein.....II-69
Biota Inc Introduces New AZT Nucleotide Mimic Drug for HIV/AIDS.....II-69
SciGen Ltd Introduces Sci-B-Vac Vaccine for Hepatitis B in Hong Kong.....II-69
1$100
   Aurobindo Pharma Ltd Launches Indivex and Stavex Anti-HIV Drugs.....II-70
Trimeris and Roche Collaboratively Develops Two Fusion Inhibitors.....II-70
1$100
   Adventrx Takes Over SD Pharmaceuticals.....II-71
Nutra Pharma to Acquire ReceptoPharm.....II-71
Dynavax Acquires German Rhein Biotech.....II-71
Barrier Acquires Rights to Market Denavir from Norvartis.....II-71
Chimerix Acquires Leroy Townsend Library of Lead Drug Candidates.....II-71
1$100
   Sareum Collaborates with Idenix to Develop Antivirals.....II-72
CSIRO Collaborates with Bath University to Create an Oral Antiviral Agent.....II-72
GlaxoSmithKline and Shionogi to Co-Develop HIV Drugs.....II-72
Inovio Biomedical Corporation Enters into an Agreement with Tripep AB.....II-72
1$100
   Roche Partners with Trimeris to Develop HIV Fusion Inhibitor Drugs.....II-73
Pfizer and Monogram Execute a Non-Exclusive Collaboration.....II-73
Novartis Enters into an Agreement with Human Genome Sciences.....II-73
Medivir Inks Licensing Deal with Tibotec for HBV and HIV Drugs.....II-73
1$100
   Boehringer to Enhance its Canadian Antiviral Research Center.....II-74
GSK Receives Pediatric Extension of Hevrix Vaccine in the US.....II-74
GSK Completes Phase II Clinical Trial on Promacta.....II-74
Schering-Plough Undertakes Clinical Trials on Some Hepatitis Products.....II-74
Gilead Sciences and Merck Conducts Clinical Trials (Phase I / II) on HIV Integrase Inhibitor.....II-74
Vertex to Start Phase IIb Trials for VX-950.....II-74
1$100
   Schering-Plough Starts Phase II Trials for SCH 503034.....II-75
Panacos Pharmaceuticals Initiates Phase 2b Studies on Bevirimat.....II-75
Immune Response Corporation Initiates IR103 Phase II Trial.....II-75
Health Enhancement Products Inc to Conduct ProAlgaZyme Clinical Trial.....II-75
Novartis Secures FDA Approval for Famvir.....II-75
1$100
   Novelos Therapeutics, Inc Gains FDA Acceptance of INDA for NOV-205.....II-76
Gilead Sciences and Bristol-Myers-Squibb Obtains FDA License for Atripla.....II-76
Tibotec Obtains FDA Approval for Darunavir.....II-76
Amazon Receives Consent for Phase I/II Trials for AMZ0026.....II-76
1$100
   MedImmune Applies for Supplemental License for CAIV-T.....II-77
FermaVir Pharmaceuticals Obtains FDA Approval for Further Studies on Antiviral Drug Candidate.....II-77
Abbott Obtains FDA Assent for ABBOTT PRISM® and PRISM® Blood Screening.....II-77
Abbott Receives Authorization from European Commission to Market Kaletra®.....II-77
Schering-Plough Receives Marketing Approval for PEG-INTRON® and REBETOL® Drugs.....II-77
1$100
   Idenix and Novartis Submit Drug Application to European Regulators for Telbivudine.....II-78
Merck Obtains FDA Approval for Marketing GARDASIL® Vaccine.....II-78
Merck’s GARDASIL Vaccine Gets CHMP’s Positive Opinion.....II-78
Boehringer Ingelheim Demonstrates the Clinical Trial Results of Aptivus® Capsules.....II-78
1$100
   GlaxoSmithKline Demonstrates Results for H5N1 Pandemic Flu Vaccine Clinical Trials.....II-79
GlaxoSmithKline Minimizes Prices of HIV Drugs in Poor Countries.....II-79
Donations Rises for AIDS Orphanage in South Africa.....II-79
FDA to Ban the Usage of Human Antiviral Drugs for Influenza Treatment in Poultry.....II-79
1$100
   Third Wave Withdraws Lawsuit against Digene Relating to Patent on HPV Drug.....II-80
Roche Files Suit against Ranbaxy to Restrain Launch of Antiviral Generic Drug.....II-80
Dainippon Pharmaceutical to Merge with Sumitomo Pharmaceuticals.....II-80
Abbott and OraSure Enter into Agreement.....II-80
Hemispherx Biopharma Signs a Research Agreement with Defence R&D Canada.....II-80
1$100
   LUPIN and Cornerstone Sign Licensing Agreement to Develop Anti-Infective
  Product.....II-81
Trimeris Inc Enters into Collaborative Agreement with ChemBridge Research Laboratories.....II-81
Corixa Corporation Collaborates with Lorantis.....II-81
Takeda Enters into HPV Collaborative Agreement with 3M.....II-81
1$100
   MedImmune Inks Collaborative Licensing Agreement with Biota.....II-82
Pharmasset Enters into License Agreement with Bukwang Pharm.....II-82
Chiron and Enanta Pharmaceuticals Enter into HCV PI Development Agreement.....II-82
Gilead Sciences Enters into JTK-303 License Agreement with Japan Tobacco.....II-82
1$100
   Alnylam and Isis Enter into Licensing Deal with Stanford University.....II-83
Gen-Probe and F. Hoffmann-La Roche Enter into an Agreement.....II-83
SciGen Limited Enters into Hepatitis B Vaccine Distribution Agreement with Berna Biotech AG.....II-83
1$100
   GSK Receives Supply Order for Relenza from Governments of Three Countries.....II-84
Bristol-Myers to Establish Production Facility in China.....II-84
Koronis Initiates Phase 1b Trial for KP-1461 Antiviral.....II-84
Gilead Initiates Phase III Clinical Trials for Tenofovir.....II-84
Vaccine Research Center Initiates Phase II Trials on Adenovector.....II-84
1$100
   Aethlon Medical Instigates Clinical Trials of HCV.....II-85
Hemispherx Biopharma Initiates Alferon LDO Clinical Trials.....II-85
Bristol-Myers and Merck Provide IPM with License to Develop HIV Vaccines.....II-85
Hi-Tech’s Acyclovir Oral Suspension Secures FDA Approval.....II-85
Bristol-Myers Squibb Gains FDA Approval for the company’s Entecavir.....II-85
1$100
   Corixa’s Fendrix® Vaccine Receives European Approval.....II-86
Calypte Biomedical’s HIV-1 Urine EIA Screening Test Receives FDA Approval.....II-86
Gilead Sciences’s Truvada® Receives Marketing Authorization.....II-86
Abbott Receives FDA Approval to Formulate Kaletra in Tablet Form.....II-86
Boehringer Ingelheim Receives EU Approval to Market Aptivus.....II-86
1$100
   Boehringer Ingelheim Secures FDA Approval to Market Aptivus.....II-87
SciClone Releases Poster Presentation of Zadaxin® Triple Therapy.....II-87
GlaxoSmithKline Discloses Clinical Findings for Brecanavir.....II-87
Abbott and Celera Secure CE Mark Certification for PCR Test.....II-87
Gilead Sciences Cuts Prices for Truvada and Viread for Developing Nations.....II-87
1$100
   Gilead Sued Roche for not Properly Marketing Tamiflu and Receives Damage
  Payment.....II-88
MGI PHARMA to Purchase Zycos.....II-88
Benitec Ltd Acquires Avocel Inc.....II-88
ID Biomedical Takes Over Vaccine Business of Shire.....II-88
1$100
   SGX Forms Alliance with Roche to Develop New Antivirals.....II-89
Epimmune and Innogenetics Extend Collaboration Agreement.....II-89
Nucleonics and Novosom Collaborate to Develop New Antivirals.....II-89
Gilead Sciences and Achillion Pharmaceuticals Sign Licensing Agreement.....II-89
1$100
   ZymoGenetics Licenses Drug Development Rights to Novo Nordisk.....II-90
Cubist and XTL Sign Development Agreement.....II-90
Sunesis and Merck Signs Research Agreement.....II-90
CytoGenix Files Pre-IND Brief with the FDA.....II-90
1$100
   ViroPharma Signs Licensing Agreement with Schering-Plough.....II-91
Hemispherx Inks Agreement with GMC for Development and Commercialization of HIV Antivirals.....II-91
DNA-C and NYVAC Combination AIDS Vaccine To Enter Clinical Trial Stage.....II-91
GlaxoSmithKline Plc Reduces Anti-AIDS Treatment Prices in Poor Countries.....II-91
1$100
   Gilead Acquires Triangle Pharmaceuticals.....II-92
Micrologix Acquires Antivirals Portfolio of Origenix.....II-92
Roche Acquires HPV Patent Portfolio from Pasteur Institute.....II-92
Johnson & Johnson Enters into an Agreement to Acquire Tibotec-Virco NV.....II-92
USL Signs Licensing Agreement with Novactyl.....II-92
1$100
   Micrologix Biotech and Hybridon Signs Collaborative Licensing Agreement.....II-93
Novartis Acquires a Portfolio of Antivirals from SmithKline Beecham.....II-93
Biota Inc’s Bird Flu Drug Relenza Receives FDA Approval.....II-93
1$100
   Abbott Laboratories (USA).....II-94
Boehringer Ingelheim (Germany).....II-94
Bristol-Myers Squibb (USA).....II-94
1$100
   Gilead Sciences (USA).....II-95
GlaxoSmithKline Plc. (UK).....II-95
1$100
   Hoffmann-La Roche (Switzerland).....II-961$100
   Merck & Co. (USA).....II-97
Novartis AG (Switzerland).....II-97
1$100
   Pfizer Inc. (USA).....II-98
Schering-Plough Corp. (USA).....II-98
1$100
   Table 26: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-991$350
   Table 27: World Recent Past, Current & Future Analysis for Antivirals by Product Segment – HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals Independently Analyzed by Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-1001$350
   Table 28: World 10-Year Perspective for Antivirals by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....II-1011$350
   Table 29: World 10-Year Perspective for Antivirals by Product Segment – Percentage Breakdown of Dollar Sales for HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....II-1021$350
   Table 30: World Recent Past, Current & Future Analysis for HIV Antivirals by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-103

Table 31: World 10-Year Perspective for HIV Antivirals by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....II-103
1$350
   Table 32: World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-104

Table 33: World 10-Year Perspective for Hepatitis B & C Antivirals by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....II-104
1$350
   Table 34: World Recent Past, Current & Future Analysis for Hepatitis C Antivirals by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-105

Table 35: World 10-Year Perspective for Hepatitis C Antivirals by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....II-105
1$350
   Table 36: World Recent Past, Current & Future Analysis for Hepatitis B Antivirals by Geographic Region – US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-106

Table 37: World 10-Year Perspective for Hepatitis B Antivirals by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....II-106
1$350
   A. Market Analysis.....III-1
Infectious Disease Drugs Market in the US.....III-1
Table 38: Infectious Disease Drugs Market by Class in the US: 2005 Percentage Share Breakdown by Type for Quinolones, Penicillins, Macrolides, Antifungals, Cephalosporins, Antivirals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart).....III-1
Antivirals Market Perspective in the US.....III-1
HIV Antivirals Dominate the Antiviral Therapies Market in the US, followed by the Hepatitis B & C Antivirals Class.....III-1
1$200
   Table 39: Antivirals Market by Type in the US: 2006 Percentage Share Breakdown for HIVAntivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart).....III-2
Combivir Dominates the Reverse Transcriptase Inhibitors Market in the US.....III-2
Table 40: Reverse Transcriptase Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Combivir, Zerit, Epivir, Sustiva, Viramune, Ziagen, Videx, Retrovir and *Others (includes corresponding Graph/Chart).....III-2
1$200
   Table 41: Leading Players in the HIV Reverse Transcriptase Inhibitors (RTIs) Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Bristol-Myers Squibb and *Others (includes corresponding Graph/Chart).....III-3
Viracept Dominates the Protease Inhibitors Market in the US.....III-3
Table 42: Protease Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Viracept, Crixivan, Norvir, Fortovase, Agenerase and Invirase (includes corresponding Graph/Chart).....III-3

Table 43: Leading Players in the HIV Protease Inhibitors (PIs) Market in the US: 2005 Percentage Share Breakdown for Abbott Laboratories, Pfizer and *Others (includes corresponding Graph/Chart).....III-3
Hepatitis B Infection Prevalence in the US.....III-3
1$200
   Hepsera Dominates the Oral Hepatitis B Antivirals Market.....III-4
Table 44: Leading Brands in the Oral Hepatitis B Antivirals Market in the US: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart).....III-4
New Emerging Therapies for HBV Infection in the US.....III-4
1$200
   Emerging Hepatitis B Infection Antivirals in Phase II Clinical Trials in the US.....III-5
Emerging Hepatitis B Infection Antivirals in Phase I Clinical Trials in the US.....III-5
Hepatitis C Antivirals Market in the US.....III-5
1$75
   Table 45: Leading Players in the Hepatitis C Antivirals Market in the US: 2005 Percentage Share Breakdown for Schering Plough and *Others.....III-6

Table 46: Leading Brands in the Interferon Hepatitis C Antivirals Market in the US: 2006 Percentage Share Breakdown for Pegasys, PEG Intron, Copegus and Rebetol (includes corresponding Graph/Chart).....III-6
HSV Antivirals in the US.....III-6
Table 47: Leading Players in the HSV Antivirals Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Generics and *Others (includes corresponding Graph/Chart).....III-6
1$200
   Influenza Antivirals Market in the US.....III-7
Emerging Influenza Antivirals in the Clinical Development Stage in the US.....III-7
TIV Dominates the US Influenza Vaccines Market.....III-7
Table 48: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Type for Treated (Killed) Influenza Vaccine (TIV) and Live Attenuated Influenza Vaccine (LAIV).....III-7
Fluzone Rules the Roost in the Influenza Vaccines Market.....III-7
1$200
   Table 49: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Brand for Fluzone, Fluvirin, Fluarix and FluMist (includes corresponding Graph/Chart).....III-8

Table 50: Leading Players in the Influenza Antivirals Market in the US: 2005 Percentage Share Breakdown for Roche and *Others.....III-8
HIV/AIDS Prevalence in the US.....III-8
1$200
   Homosexual Males Emerges as a Significant Risk Group for HIV Infections in the
  US.....III-9
Table 51: Diagnosis of HIV/AIDS among Adult and Adolescent Males in the US: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug User (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart).....III-9
1$200
   Table 52: Ethnic Group Distribution of HIV/AIDS Cases Among Men with Homosexual Contacts in the US: 2005 Percentage Share Breakdown for Whites, African Americans, Latin Americans, Asian/Pacific Islander and American Indian/Alaska Native (includes corresponding Graph/Chart).....III-10
Women, a High Risk Group for HIV/AIDS in the US.....III-10
Table 53: AIDS Cases Reported in the US Among Females 13 and Older: 2005 Percentage Share Breakdown by Ethnic Community for African American Women, Latin American Women, White Women and Others (includes corresponding Graph/Chart).....III-10

Table 54: Diagnosis of HIV/AIDS among Adult and Adolescent Females in the US: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug User (IDU) and Others (includes corresponding Graph/Chart).....III-10
1$200
   African Americans, the Leading High Risk Ethnic Group for HIV Infection in the US.....III-11
Table 55: Individuals Living with AIDS in the US: 2005 Percentage Share Breakdown by Ethnic Community for African Americans, Whites, Latin Americans and Others (includes corresponding Graph/Chart).....III-11
Latinos, the Second Major Ethnic Risk Group for HIV Infection in the US.....III-11
Zidovudine (ZDV) Emerges as a Major Drug to Prevent Mother-to-Child Transmission of HIV Infection.....III-11
An Overview of Sexually Transmitted Diseases (STDs) in the US.....III-11
1$200
   Regulatory Environment for HIV/AIDS in the US.....III-12
Product Launches.....III-12
2$150
   Strategic Corporate Developments.....III-1413$525
   Focus on Key Players.....III-27
3M.....III-27
Abbott Laboratories.....III-27
1$75
   Amazon Biotech.....III-28
Bristol-Myers Squibb.....III-28
1$75
   FermaVir Pharmaceuticals.....III-29
Gilead Sciences.....III-29
Hemispherx Biopharma.....III-29
1$75
   MedImmune Inc......III-30
Merck & Co......III-30
Novartis Pharmaceuticals.....III-30
1$75
   Novelos Therapeutics.....III-31
Panacos Pharmaceuticals.....III-31
Pfizer Inc......III-31
Pharmasset.....III-31
1$75
   Schering-Plough Corporation.....III-32
B. Market Analytics.....III-32
Table 56: US Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).III-32
1$200
   Table 57: US Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment – RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-33

Table 58: US 10-Year Perspective for HIV Antivirals by Product Segment – Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....III-33
1$200
   Table 59: US Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment – Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-34

Table 60: US 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment – Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis BAntivirals for the Years 2000, 2006 & 2010.....III-34
1$200
   A. Market Analysis.....III-35
Japanese Antivirals Market Perspective.....III-35
HIV Infection Prevalence in Japan.....III-35
Hepatitis B & C Antivirals Dominate the Japanese Antivirals Market.....III-35
Japan, the Second Largest Market for Hepatitis C Infection in the World.....III-35
1$75
   Table 61: Leading Drug Brands for Hepatitis C Antivirals in Japan: 2005, 2006 and 2008E Percentage Share Breakdown for PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon, Feron and Others (includes corresponding Graph/Chart).....III-36
Product Launch.....III-36
Strategic Corporate Developments.....III-36
1$200
   Focus on Key Players.....III-37
Daiichi Pharmaceutical Co......III-37
1$75
   Japan Tobacco.....III-38
B. Market Analytics.....III-38
Table 62: Japanese Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-38
1$200
   Table 63: Japanese Recent Past, Current & Future Analysis for HIV Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-39

Table 64: Japanese Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment – Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-39

Table 65: Japanese 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment – Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010 .....III-39
1$200
   A. Market Analysis.....III-40
France - The Largest and the Fastest Growing Market for Antivirals.....III-40
HIV Therapy Dominates the Antivirals Market.....III-40
Table 66: Antivirals Market by Type in Europe: 2006 Percentage Share Breakdown for HIV Antivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart).....III-40
1$200
   HIV/AIDS Prevalence in Europe.....III-41
HIV/AIDS Statistics in Western Europe.....III-41
UK Dominates the Market for Western Europe for HIV Infection.....III-41
Table 67: Diagnosis of HIV Infection among Adults in Western Europe: 2005 Percentage Share Breakdown by Region for UK, Portugal, **France, Germany, The Netherlands, *Italy, Belgium, Switzerland and Others (includes corresponding Graph/Chart).....III-41
1$200
   HIV/AIDS Statistics in Central Europe.....III-42
Poland Dominates the Market for Central Europe for HIV Infection.....III-42
Table 68: Diagnosis of HIV Infection among Adults in Central Europe: 2005 Percentage Share Breakdown by Region for Poland, Romania, Turkey, Serbia & Montenegro, Czech Republic, Hungary, Bulgaria and Others (includes corresponding Graph/Chart).....III-42
HIV/AIDS Statistics in Eastern Europe.....III-42
Russia Dominates the Market for Eastern Europe for HIV Infection.....III-42
1$200
   Table 69: Diagnosis of HIV Infection among Adults in Eastern Europe: 2005 Percentage Share Breakdown by Region for Russia, *Ukraine, Uzbekistan, Belarus, Estonia, Kazakhstan, Republic of Moldova, Latvia and Others (includes corresponding Graph/Chart).....III-43
Herpes Antivirals.....III-43
Strategic Corporate Developments.....III-43
3$400
   B. Market Analytics.....III-46
Table 70: European Recent Past, Current & Future Analysis for Antivirals by Geographic Region – France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-46

Table 71: European 10-Year Perspective for Antivirals by Geographic Region – Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain and Rest of Europe for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....III-46
1$200
   Table 72: European Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment – RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-47

Table 73: European 10-Year Perspective for HIV Antivirals by Product Segment –Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....III-47
1$200
   Table 74: European Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment – Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-48

Table 75: European 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment– Percentage Breakdown of Value Sales for Hepatitic C Antivirals and Hepatitis B Antivirals for Years 2000, 2006 & 2010.....III-48
1$200
   A. Market Analysis.....III-49
France the Largest and Fastest Growing Antivirals Market in Europe.....III-49
Strategic Corporate Developments.....III-49
B. Market Analytics.....III-49
Table 76: French Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-49
1$200
   A. Market Analysis.....III-50
Germany the Second Largest and Fastest Growing Antivirals Market in Europe.....III-50
Strategic Corporate Developments.....III-50
1$75
   Focus on Key Player.....III-51
Boehringer Ingelheim.....III-51
B. Market Analytics.....III-51
Table 77: German Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-51
1$200
   A. Market Analysis.....III-52
Strategic Corporate Developments.....III-52
B. Market Analytics.....III-52
Table 78: Italian Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-52
1$200
   Market Analysis.....III-53
UK the Third Largest Market for Antivirals in Europe.....III-53
HIV/AIDS Prevalence in the UK.....III-53
Table 79: Diagnosis of HIV Infection among Individuals in the UK: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Black- Africans, Black-Caribbeans and Others (includes corresponding Graph/Chart).....III-53
1$200
   Table 80: Diagnosis of AIDS among Adult Males in the UK: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart).....III-54

Table 81: Diagnosis of AIDS among Adult Females in the UK: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Mother-to-Child Transfer, Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart).....III-54

Table 82: Diagnosis of HIV Infection in People in the UK: 2005 Percentage Share Breakdown by Region for England, Scotland, Wales and North Ireland (includes corresponding Graph/Chart).....III-54
Drug Resistant HIV Strains Rising in the UK.....III-54
Rise in Sexually Transmitted Diseases Pose Health Risks.....III-54
1$200
   Strategic Corporate Developments.....III-55
Focus on Key Player.....III-55
GlaxoSmithKline PLC.....III-55
1$75
   B. Market Analytics.....III-56
Table 83: UK Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-56
1$200
   A. Market Analysis.....III-57
Market Analysis.....III-57
B. Market Analytics.....III-57
Table 84: Spanish Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-57
1$200
   A. Market Analysis.....III-58
Russia.....III-58
Acute Supply Shortage of AIDS drugs Risks the Life of Many People in Russia.....III-58
Strategic Corporate Developments.....III-58
2$150
   Focus on Key Players.....III-60
Hoffmann-La Roche (Switzerland).....III-60
1$75
   Novartis AG (Switzerland).....III-61
B. Market Analytics.....III-61
Table 85: Rest of Europe Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).III-61
1$200
   A. Market Analysis.....III-62
Canada.....III-62
HIV/AIDS Prevalence in Canada.....III-62
Table 86: Diagnosis of HIV Infection among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU, Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart).....III-62
1$200
   Table 87: Diagnosis of HIV Infection among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart).....III-63

Table 88: Diagnosis of AIDS among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart).....III-63

Table 89: Diagnosis of AIDS among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU) and Others (includes corresponding Graph/Chart).....III-63
1$200
   Table 90: Individuals Living with AIDS in Canada: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Aboriginals, Blacks, South Asian/West Asian/Arab, Asians and Others (includes corresponding Graph/Chart).....III-64
Hepatitis C Infection Prevalence in Canada.....III-64
Asia-Pacific.....III-64
HIV/AIDS Prevalence in Asia.....III-64
HIV Infection Among Males Rising.....III-64
1$200
   Australia.....III-65
HIV/AIDS Prevalence in Australia.....III-65
Table 91: Diagnosis of HIV Infections in Australia: 2005 Percentage Share Breakdown by Region for New South Wales, Victoria, Queensland, Western Australia, South Australia, Australian Capital Territory and Others (includes corresponding Graph/Chart).....III-65
Hepatitis C Infection Prevalence in Australia.....III-65
1$200
   Table 92: Sources of Hepatitis C Infection Transmission in Australia: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Blood Transfusion/Medical, Tattoos/Piercing, Sexual Contact and Others (includes corresponding Graph/Chart).....III-66
Bangladesh.....III-66
HIV/AIDS Prevalence in Bangladesh.....III-66
Cambodia.....III-66
HIV/AIDS Prevalence in Cambodia.....III-66
China.....III-66
Antivirals Market in China.....III-66
1$200
   China Presents a Major Market for Hepatitis B Therapies.....III-67
HIV/AIDS Prevalence in China.....III-67
Hong Kong.....III-67
HIV/AIDS Prevalence in Hong Kong.....III-67
1$75
   India.....III-68
Hepatitis B Vaccines Market in India.....III-68
Table 93: Hepatitis B Vaccine Market in India: 2005 Percentage Share Breakdown by Player for Shantha Biotech, Glaxo SmithKline and Others (includes corresponding Graph/Chart).....III-68
HIV/AIDS Prevalence in India.....III-68
1$200
   Table 94: AIDS Cases Diagnosed in India: 2005 Percentage Share Breakdown by Gender for Males and Females.....III-69

Table 95: Diagnosis of HIV/AIDS Cases in India: 2005 Percentage Share Breakdown by Transmission Category for Sexual Contact, Mother-to-Child Transfer, Injecting Drug Use (IDU), Blood and Blood Products, and Others (includes corresponding Graph/Chart).....III-69

Table 96: Diagnosis of AIDS Cases in India: 2005 Percentage Share Breakdown by Geographic Region for Tamil Nadu, Maharashtra, Andhra Pradesh, Karnataka, Manipur, West Bengal, Kerala, Madhya Pradesh, Uttar Pradesh, Rajasthan and Others (includes corresponding Graph/Chart).....III-69
1$200
   India Emerging as a Major Market for HIV-Infected People in the World.....III-70
Table 97: Diagnosis of HIV Infection in India: 2005 Percentage Share Breakdown by Sub-Population for General Population, STD Patients, Injecting Drug Users (IDUs), Children and Female Sex Workers (FSWs) (includes corresponding Graph/Chart).....III-70
Organizations Active in Executing HIV/AIDS Control and Prevention
  Programs.....III-70
1$200
   Table 98: Institutional Funding for HIV/AIDS Control Programs in India: 2005 Percentage Share Breakdown by Funding Organization for Public Bodies, Bilateral Organizations, World Bank, Multilateral Organizations and Global Funds (includes corresponding Graph/Chart).....III-71
India Steps Up Infrastructure Development to Control and Prevent the Spread of
  Viral Infections.....III-71
New Treatment Options to Fight Against HIV Infection.....III-71
1$200
   AIDS Control Programs for Rural Youths in India.....III-72
Indonesia.....III-72
HIV/AIDS Prevalence in Indonesia.....III-72
Myanmar (Burma).....III-72
HIV/AIDS Prevalence in Myanmar.....III-72
Nepal.....III-72
HIV/AIDS Prevalence in Nepal.....III-72
1$75
   New Zealand.....III-73
HIV/AIDS Prevalence in New Zealand.....III-73
Pakistan.....III-73
HIV/AIDS Prevalence in Pakistan.....III-73
Singapore.....III-73
HIV/AIDS Prevalence in Singapore.....III-73
South Korea.....III-73
HIV/AIDS Prevalence in South Korea.....III-73
Thailand.....III-73
HIV/AIDS Prevalence in Thailand.....III-73
1$75
   Viet Nam.....III-74
HIV/AIDS Prevalence in Viet Nam.....III-74
Hepatitis B Infection Prevalence in Viet Nam.....III-74
Latin America.....III-74
HIV/AIDS Prevalence in Latin America.....III-74
1$75
   Table 99: Diagnosis of People Living with HIV/AIDS in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Mexico, Colombia, Argentina, Venezuela, Peru, Honduras, Guatemala, El Salvador, Ecuador, Panama, Paraguay and Others (includes corresponding Graph/Chart).....III-75

Table 100: Diagnosis of AIDS Related Deaths in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Colombia, Mexico, Venezuela, Peru, Argentina, Honduras, Guatemala, El Salvador, Ecuador, Panama and Others (includes corresponding Graph/Chart).....III-75
1$200
   HIV/AIDS Prevalence in the Caribbean Region.....III-76
Table 101: Diagnosis of People Living with HIV/AIDS in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica, Bahamas, Cuba and Barbados (includes corresponding Graph/Chart).....III-76
1$200
   Table 102: Diagnosis of AIDS Related Deaths in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica and Others (includes corresponding Graph/Chart).....III-77
Africa.....III-77
HIV/AIDS Prevalence in Sub-Saharan Africa.....III-77
Table 103: Diagnosis of People Living with HIV/AIDS in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Mozambique, Zimbabwe, United Republic of Tanzania, Kenya, Ethiopia, Zambia, Democratic Republic of Congo, Uganda and Others (includes corresponding Graph/Chart).....III-77
1$200
   Table 104: Diagnosis of AIDS Related Deaths in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Zimbabwe, Mozambique, United Republic Of Tanzania, Kenya, Ethiopia, Zambia, Uganda, Malawi and Others (includes corresponding Graph/Chart).....III-78

Table 105: Diagnosis of AIDS Related Orphans in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Kenya, United Republic Of Tanzania, Zimbabwe, Uganda, Nigeria, Ethiopia, Zambia, Democratic Republic of Congo, Malawi and Others (includes corresponding Graph/Chart).....III-78
1$200
   South Africa.....III-79
Television Exposures Induces Healthy Lifestyle Changes Among People to Combat HIV/AIDS Epidemic.....III-79
HIV/AIDS Prevalence in South Africa.....III-79
Middle East.....III-79
HIV/AIDS Prevalence in Middle East.....III-79
1$75
   Product Launches.....III-801$75
   Strategic Corporate Developments.....III-814$175
   Focus on Select Players.....III-85
Bukwang Pharm (South Korea).....III-85
Benitec Limited (Australia).....III-85
B. Market Analytics.....III-85
Table 106: Rest of World Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-85
1$200
   Table 107: Rest of World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment – Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart).....III-86

Table 108: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment – Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart).....III-86

Table 109: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment – Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010.....III-86
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com